Objective Confirmation of thе Anti-ischemic Effectiveness of Trimetazidine 80mg Once Daily in Patients With Stable Angina Who Had a History of Myocardial Infarction (METHOD)

Inclusion Criteria: * Age older than 18 yearsAge older than 18 years * Signed informed consent form * Stable angina pectoris (CCS I-III FC) with signs of myocardial ischemia despite treatment with antianginal drug(s) present either clinically and/ or at stress ECHO test with dobutamine * History of myocardial infraction occurred 6 months and more from the inclusion date * Trimetazidine (TMZ) is recommended as add on to the current antianginal treatment and this recommendation precedes inclusion of a patient in the study * Intention to perform a stress echo with spackle tracking precedes the start of TMZ * Physician's intention to perform a stress ECHO test within a 6-month period after the date of inclusion in the study Exclusion Criteria: * Age over 75 years or under 18 years old * Hypersensitivity to the active substance or any excipient specified in SmPc of TMZ 80 mg OD * Parkinson's disease, parkinsonism symptoms, tremors, restless legs syndrome and other accompanying movement disorders * Known severe or moderate renal impairment (creatinine clearance \<60 ml / min). * Angina pectoris of IV functional CCS class * Heart failure IV functional class by NYHA * Cardiac valves insufficiency with regurgitation of stage III and higher * Myocardial infarction less than 6 months from the inclusion date * Acute cerebrovascular event (stroke of various origins, transient ischemic attack) within 6 months before screening date * Uncontrolled arterial hypertension of stage 3 (blood pressure above 180/100 mm Hg) despite ongoing antihypertensive therapy * Fructose / sucrose intolerance, presence of glucose-galactose malabsorption syndrome, sucrose-somaltase deficiency and other enzymopathies associated with intolerance to sucrose, which is part of the drug * Pregnancy, breastfeeding * Any contraindications to stress echocardiography with dobutamine